drugset / Trial / NCT06782334

AMT-116 in Patients with Solid Tumors

NCT06782334

Phase 1/2 Recruiting 144 enrolled Multitude Therapeutics Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of AMT-116 monotherapy in subjects with advanced solid tumors. The study is divided into two parts: the part I is dose escalation and the Part Ⅱ for expansion.

Timeline

Start
2024-05-07
Primary completion
2026-06-30
Completion
2026-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject AMT-116 Other / unclassified

Indications